Digest Network Come funziona
Network
/
Società
Ma
Non verificato

Massive Bio

Di cosa scriviamo

IndustriaMedicina - VarieMultimedialitàOncologiaSalute

23 comunicati stampa

Guarda tutti i comunicati
03/06/2026
Massive Bio and Optellum Collaborate to Accelerate Clinical Trial Access for Early-Stage Non-Small Cell Lung Cancer Patients
Fonte
Massive Bio
Emittente
Business Wire
1.00
0
30/05/2026
Massive Bio Announces Next-Generation Reticulum Nexus™ Product Suite at ASCO 2026
Fonte
Massive Bio
Emittente
Business Wire
1.00
0
29/05/2026
Massive Bio Partners with TOUCH, The Black Breast Cancer Alliance and Navigating Trials to Expand Cancer Patients' Access to Clinical Trials
Fonte
Massive Bio
Emittente
Business Wire
1.00
0
28/05/2026
Massive Bio to Unveil Reticulum Nexus™ as the AI Operating System for Oncology Access at ASCO 2026
Fonte
Massive Bio
Emittente
Business Wire
1.00
0
21/05/2026
Massive Bio and BeeKeeperAI Deploy Federated Confidential Computing to Expand Oncology Trial Access Across Atlanta’s Underserved Communities
Fonte
Massive Bio
Emittente
Business Wire
1.00
0
14/05/2026
Massive Bio and Just Worldwide Announce Strategic Partnership to Connect More Cancer Patients to Clinical Trials
Fonte
Massive Bio
Emittente
Business Wire
1.00
0
28/04/2026
Massive Bio Expands Global Access to Clinical Trials Through AI-Powered Parameterization and Pre-Screening with OpenAI
Fonte
Massive Bio
Emittente
Business Wire
1.00
0
09/04/2026
Massive Bio Publishes Landmark Prospective Study Demonstrating AI-Driven Clinical Trial Matching at Scale in 3,804 Cancer Patients
Fonte
Massive Bio
Emittente
Business Wire
1.00
0
19/03/2026
Massive Bio Launches NexusPulse™, the Real-Time AI Signal Engine for Oncology Markets
Fonte
Massive Bio
Emittente
Business Wire
1.00
0
02/02/2026
Massive Bio Launches TrialRelay™ at SCOPE 2026: An Operating System to End "Referral Black Holes" in Oncology
Fonte
Massive Bio
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0